Dr. Zoubeidi's project rated as Top 5 Research Story at PCF Scientific Retreat

Date Posted: 
2018-11-28

Dr. Amina Zoubeidi's project, Reversing Neuroendocrine Prostate Cancer (NEPC), was  rated as one of the Top 5 Research Stories at The 25th Annual Prostate Cancer Foundation Scientific Retreat, held October 26- 28, at the La Costa Resort in Carlsbad, CA.

The Prostate Cancer Foundation's Science Department rated the topics or discoveries discussed during the Scientific Retreat, and described each of the top five on their website. For Dr. Zoubeidi, the description is:
Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal form of prostate cancer that affects ~17% of patients with advanced CRPC. Because this form of prostate cancer is so aggressive, there is an urgent need to develop new and effective treatments for patients with NEPC. PCF-funded researcher Dr. Amina Zoubeidi (Vancouver Prostate Centre) has discovered a “regulator” gene (EZH2) that controls NEPC. When enzalutamide-resistant prostate cancer cells are given EZH2-inhibitors, they revert and become treatable again with enzalutamide. EZH2 inhibitors are now in clinical trials for advanced prostate cancer.

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC took place on Sunday June 16, 2019 in various locations across BC. The sponsorship page is still accepting donations;  click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Tuesday, June 11, 2019

Dr. Cox featured in VCHRI News

Dr. Cox and family
Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi